Head of Investor Relations
Collegium Pharmaceutical, Inc (COLL)Head of Investor Relations
Intellia Therapeutics, Inc. (NTLA)Equibles does not estimate personal net worth.
Get an email with a short summary when Collegium Pharmaceutical, Inc publishes a filing, an earnings call transcript or a press release.
Get COLL alertsIan Karp is recorded as Head of Investor Relations at Collegium Pharmaceutical, Inc (COLL) and Head of Investor Relations at Intellia Therapeutics, Inc. (NTLA). Ian Karp has spoken on 18 earnings calls and 1 other investor event across 3 companies, most recently for Collegium Pharmaceutical, Inc on August 6, 2026. Those appearances were for Intellia Therapeutics, Inc. (NTLA), Collegium Pharmaceutical, Inc (COLL) and Karyopharm Therapeutics Inc. (KPTI). Intellia Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Collegium Pharmaceutical, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Intellia Therapeutics, Inc. includes Edward J. Dulac III (CFO), Andrew D. Schiermeier (COO), James Basta (General Counsel) and 7 others.
“Thanks so much, and welcome to Collegium Pharmaceuticals' second quarter 2026 earnings conference call. I'm joined today by Vikram Karnani, our president and chief executive officer, and Colleen Tupper, our chief financial officer.”
“And welcome to Collegium Pharmaceuticals' first quarter 2026 earnings conference call. I'm joined today by Vikram Karnani, our President and Chief Executive Officer, Colleen Tupper, our Chief Financial Officer, and Scott Dreyer, our Chief Commercial Officer.”
“Thanks so much. and welcome to Collegium Pharmaceutical Investor Call to discuss the acquisition of Astaris and all relevant corporate subsidiaries from Corium Therapeutics, which significantly expands our position in ADHD.”
“Welcome to Collegium Pharmaceuticals' fourth quarter and full year 2025 earnings conference call. I'm joined today by Vikram Karnani, our president and chief executive officer, Colleen Tupper, our chief financial officer, and Scott Dreyer, our chief commercial officer.”
“Thanks, and welcome to Collegium Pharmaceuticals Second Quarter 2025 Earnings Conference Call. I'm joined today by Vikram Karnani, our President and Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.”
Source not stated
Biotechnology · Healthcare
Head of Investor Relations
Drug Manufacturers - Specialty & Generic · Healthcare
Head of Investor Relations
Biotechnology · Healthcare
